The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus.

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to manufacturers whose sales fell sharply last year.

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of respiratory syncytial virus vaccines in younger adults who are at increased risk of severe illness from the virus.